Table 2.
Association of Osteopontin splice variants with various cancers and their stage in TSVdb. Only the significant p-values (< 0.05 according to one-tailed t-test assuming equal variance) are listed. Left Panel) Comparison of cancer versus healthy (normal) tissue (h), primary tumor versus metastasis (m), or original cancer versus recurrence (r). All significant changes are high in cancer/in metastasis/in recurrence. Right panel) Significant changes in Osteopontin splice variant expression with tumor stage. Where multiple stages are significant, the highest p-value is listed and the smallest n. With the exception of entries in italics, all significant changes reflect increases. I/II = stage I versus stage II, I/III = stage I versus stage III, I/IV = stage I versus stage IV, II/IV = stage II versus stage IV, 6,7,8,9,10 = Gleason stages
| cancer | cancer | stage | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | OPN-a | OPN-b | OPN-c | OPN-4 | OPN-5 | n | OPN-a | OPN-b | OPN-c | OPN-4 | OPN-5 | |
| adrenocortical carcinoma | 79 | |||||||||||
| pheochromocytoma/paraganglioma | 187 | |||||||||||
| kidney chromophobe | 91 | 41 | 0.039 (I/IV) | |||||||||
| renal clear cell carcinoma | 605 | 11.6E-5 (h) | 2.5E-5 (h) | 500 | 15.3E-3 (I/II,I/III) | |||||||
| renal papillary cell carcinoma | 323 | 1.02E-5 (h) | 2.67E-3 (h) | 2.21E-6 (h) | 2.77E-6 (h) | 210 | 0.011 (I/II) | 4.8E-3 (I/II) | ||||
| bladder urothelial carcinoma | 427 | |||||||||||
| prostate adenocarcinoma | 550 | 550 | 0.03 (6/7–6/10) | 0.02 (6/7–6/10) | 0.04 (6/7–6/10) | |||||||
| testicular germ cell tumor | 156 | 82 | 0.028 (I/II,I/III) | 0.011 (I/III) | 0.004 (I/III) | |||||||
| ovarian serous cystadenocarcinoma | 307 | 4.67E-2 (r) | ||||||||||
| cervical cancers | 309 | |||||||||||
| endometrial carcinoma | 201 | 0.022 (h) | 0.018 (h) | 3.78E-3 (h) | ||||||||
| uterine carcinosarcoma | 57 | 42 | 0.02 (I/III) | |||||||||
| breast adenocarcinoma | 1212 | 6.11E-9 (h) | 2.27E-10 (h) | 5.45E-5 (h) | 222 | 0.034 (I/IV) | ||||||
| esophageal carcinoma | 196 | 163 | 0.028 (I/II,I/III,I/IV) | 0.028 (I/II,I/III,I/IV) | 0.035 (I/II,I/III,I/IV) | 0.012 (I/II,I/III) | 0.048 (I/II,I/III,I/IV) | |||||
| stomach adenocarcinoma | 450 | 0.019 (h) | 0.039 (h) | 0.034 (h) | 0.029 (h) | 0.043 (h) | 65 | 0.037 (I/IV) | 0.036 (I/IV) | 0.022 (I/IV) | ||
| colon adenocarcinoma | 328 | 4.53E-4 (h) | 3.58E-4 (h) | 4.17E-4 (h) | 137 | 0.012 (I/III) | 0.022 (I/III) | 0.011 (I/III) | 0.007 (I/III) | |||
| rectum adenocarcinoma | 105 | 31 | 0.007 (I/IV) | 0.012 (I/IV) | 0.010 (I/IV) | 0.023 (I/IV) | ||||||
| cholangiocarcinoma | 45 | 9.90E-3 (h) | 3.27E-3 (h) | 22.4E-3 (h) | 8.06E-3 (h) | |||||||
| hepatocellular carcinoma | 423 | 8.22E-4 (h) | 6.36E-3 (h) | 7.05E-3 (h) | 6.69E-3 (h) | 196 | 1.72E-4 (I/IV) | |||||
| pancreatic adenocarcinoma | 183 | 5.15E-4 (h) | 1.28E-3 (h) | 3.84E-3 (h) | 5.72E-2 (h) | 72 | 0.020 (I/II) | 0.016 (I/II) | 0.013 (I/II) | |||
| lung adenocarcinoma | 576 | 1.73E-6 (h) | 0.013 (h) | 2.17E-6 (h) | 1.02E-5 (h) | |||||||
| lung squamous cell carcinoma | 552 | 1.05E-6 (h) | 0.021 (h) | 3.70E-5 (h) | 8.42E-3 (h) | 361 | 0.031 (I/II) | 0.015 (I/III) | 0.020 (I/II) | |||
| mesothelioma | 87 | |||||||||||
| thyroid carcinoma | 568 | 0.010 (h) | 0.013 (h) | 0.022 (h) | 382 | 0.034 (I/II,I/III) | 0.035 (I/II) | 0.021 (I/II,I/III) | 0.008 (I/III) | 0.026 (I/III) | ||
| thymoma | 122 | 43 | 0.021 (I/IV) | 0.025 (I/IV) | 0.028 (I/IV) | 0.016 (I/IV) | 0.005 (I/IV) | |||||
| diffuse large B-cell lymphoma | 48 | |||||||||||
| acute myeloid leukemia | 173 | |||||||||||
| head and neck cancer | 566 | 0.013 (h) | 0.040 (h) | 9.9E-3 (h) | 0.039 (h) | 119 | 0.028 (I/II,I/IV) | 0.001 (I/II) | 0.025 (I/II,I/IV) | 0.013 (I/II) | ||
| glioblastoma | 171 | 37.5E-3 (h) | 35.9E-3 (h) | 23.4E-3 (h) | ||||||||
| brain lower grade glioma | 530 | |||||||||||
| cutaneous melanoma | 473 | 0.012 (m) | 0.028 (m) | 2.67E-3 (m) | 0.01 (m) | 102 | 0.026 (I/IV) | 5.77E-3 (I/IV) | 17.9E-3 (I/II) | |||
| uveal melanoma | 80 | |||||||||||
| sarcoma | 265 |